Lantheus Holdings, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?

Comparing R&D investments: Corcept vs. Lantheus

__timestampCorcept Therapeutics IncorporatedLantheus Holdings, Inc.
Wednesday, January 1, 20141837200013673000
Thursday, January 1, 20151541900014358000
Friday, January 1, 20162384400012203000
Sunday, January 1, 20174037600018125000
Monday, January 1, 20187524700017071000
Tuesday, January 1, 20198901700020018000
Wednesday, January 1, 202011476400032788000
Friday, January 1, 202111386400044966000
Saturday, January 1, 2022130991000311681000
Sunday, January 1, 202318435300077707000
Loading chart...

Data in motion

Innovation Investment: A Tale of Two Companies

In the competitive landscape of the pharmaceutical and biotechnology sectors, innovation is the lifeblood of progress. Over the past decade, Corcept Therapeutics Incorporated and Lantheus Holdings, Inc. have demonstrated contrasting approaches to research and development (R&D) investments.

Corcept's Steady Climb

Corcept Therapeutics has consistently increased its R&D spending, with a notable 900% rise from 2014 to 2023. This upward trajectory underscores their commitment to pioneering treatments, particularly in the field of endocrinology.

Lantheus' Strategic Surge

Conversely, Lantheus Holdings experienced a dramatic spike in 2022, with R&D expenses soaring to over 300% of their previous year's investment. This strategic surge highlights their focus on advancing diagnostic imaging solutions.

Both companies exemplify different yet effective strategies in fostering innovation, reflecting their unique market positions and long-term visions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025